Any current/future new fundraising through debt or equity?

The management did not provide any specific details regarding current or future fundraising through debt or equity in the provided content. Ajay Mahajan mentioned inorganic growth as a possibility but emphasized caution due to regulatory constraints and valuation concerns. The company continues to scout for inorganic opportunities but has no committed timeline for investments. No explicit mention of planned debt or equity fundraising was made. The focus remains on organic growth, strengthening business segments, and executing strategic objectives. Overall, the company prefers a conservative ap

Any current/future capex/capital investment/strategic investment?

The company is investing in technology as a key differentiator for diversification and growth; Q2 included data center migration, system security enhancement, and end-user technology upgrades. Planned investments in technology across CARE Ratings, CARE Risk Solutions, and CARE Advisory include deploying artificial intelligence and machine learning to enhance efficiency and rationalize costs. The company is open to both organic and inorganic growth strategies; actively scouting for inorganic opportunities, especially in tech-based platforms and analytics, though no specific timeline or commitme

Future growth expectations in sales/revenue/volumes?

The company aims to regain and grow market share in the ratings business by at least 1% per annum over the next 3-4 years, targeting a return to high 20% market share from the current low 20s. It expects moderate revenue growth in the rating segment, contingent on credit market expansion in India. Non-rating businesses (CARE Advisory and CARE Risk Solutions) are targeted to contribute about one-third of total revenue and earnings by March 2025, reflecting diversification and significant growth potential. The company is preparing to accelerate growth substantially as credit markets pick u

Future growth expectations in earnings/operating earnings/profits/EPS?

CARE Ratings aims to regain and increase market share by at least 1% per annum over the next 3-4 years, targeting mid to high 20s market share from low 20s currently. Moderate growth in rating revenues expected with industry credit growth; revenue improved ~6% H1 YoY despite challenging macro environment. Non-rating business targeted to contribute about one-third of total revenue and earnings by March 2025, indicating significant diversification and growth. The company plans to accelerate growth driven by strong teams, technology investments, and inorganic opportunities, though inorganic growt

CARE RatingsQ2 FY22Capital Markets

CARE Ratings Q2 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,620.2P/E: 27.5Market Cap: ₹4.9K CrSector: Capital Markets

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company aims to regain and grow market share in the ratings business by at least 1% per annum over the next 3-4 years, targeting a return to high 20% market share from the current low 20s.
It expects moderate revenue growth in the rating segment, contingent on credit market expansion in India.
Non-rating businesses (CARE Advisory and CARE Risk Solutions) are targeted to contribute about one-third of total revenue and earnings by March 2025, reflecting diversification and significant growth potential.
The company is preparing to accelerate growth substantially as credit markets pick up, with an overall strategy targeting significant revenue momentum and CAGR over the next three years.
Both organic growth and selective inorganic opportunities (technology or platform acquisitions) are part of the future growth strategy, although no specific timelines are given.
Continuous investment in technology, talent acquisition, and business development underpins this growth outlook.

Margin guidance

Category 3

CARE Ratings aims to regain and increase market share by at least 1% per annum over the next 3-4 years, targeting mid to high 20s market share from low 20s currently.
Moderate growth in rating revenues expected with industry credit growth; revenue improved ~6% H1 YoY despite challenging macro environment.
Non-rating business targeted to contribute about one-third of total revenue and earnings by March 2025, indicating significant diversification and growth.
The company plans to accelerate growth driven by strong teams, technology investments, and inorganic opportunities, though inorganic growth timeline is uncertain.
EPS and profitability expected to improve as credit markets pick up; cost pressures (employee/IT/CSR) recognized but controlled.
EBITDA margins currently challenged by low industry growth but improve as revenue scale rises.
Overall, a significant medium-term growth momentum in revenues and profits is expected through market share gains, diversification, and operational execution.

See what CARE Ratings management said on margin guidance — free account, 30 seconds.

Fundraise plans

The management did not provide any specific details regarding current or future fundraising through debt or equity in the provided content.
Ajay Mahajan mentioned inorganic growth as a possibility but emphasized caution due to regulatory constraints and valuation concerns.
The company continues to scout for inorganic opportunities but has no committed timeline for investments.
No explicit mention of planned debt or equity fundraising was made.
The focus remains on organic growth, strengthening business segments, and executing strategic objectives.
Overall, the company prefers a conservative approach towards capital allocation and growth investments at present.

Order book

The provided pages of the document do not mention any details regarding the current or expected order book or pending orders. The discussion primarily revolves around: - Revenue performance, market share, and receivables - Industry challenges and growth opportunities - Regulatory environment and corporate bond markets - Competitive positioning and strategy on rating and non-rating businesses - Investments in technology and talent acquisition - Accounting changes affecting receivables and outlook on non-cooperation category issuers No specific data or commentary related to order book status or pending orders is provided in the transcript. If you have another section or document with such details, please share for more targeted information.

See what CARE Ratings management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is investing in technology as a key differentiator for diversification and growth; Q2 included data center migration, system security enhancement, and end-user technology upgrades.
Planned investments in technology across CARE Ratings, CARE Risk Solutions, and CARE Advisory include deploying artificial intelligence and machine learning to enhance efficiency and rationalize costs.
The company is open to both organic and inorganic growth strategies; actively scouting for inorganic opportunities, especially in tech-based platforms and analytics, though no specific timeline or commitments have been made.
Focus remains on acquiring and retaining high-quality human resources to support growth.
Capital expenditure is expected on technology and IT infrastructure, considered a strategic investment and key enabler of transformation.
CSR expenses and professional/legal fees are considered non-discretionary and somewhat inelastic costs.
No specific mention of large-scale capex projects beyond IT and technology upgrades.

Track CARE Ratings — get its next earnings analysis in your feed

How does CARE Ratings rank vs peers in Capital Markets?

Pro feature

ThisCARE Ratings

Rev 3Mar 3

See where CARE Ratings sits in Capital MarketsSee which companies these are, and every other name in the sector.Open rankings

How does CARE Ratings rank in Capital Markets?

Compare CARE Ratings against every Capital Markets company (Q2 FY22) on revenue, margins and earnings-call signals.

View Capital Markets leaderboard →

What CARE Ratings's management said in earlier quarters

Others in Capital Markets this season

Computer Age Management Services Ltd (Q2 FY27)
Q2 FY’27 Revenue from operations: ₹41,446.57 Lakh, up 10.0% YoY (₹37,673.79 Lakh in Q2 FY’26). Key investor presentation takeaways from Computer Age Management
ICRA (Q2 FY27)
Q2 FY2027 Group Revenue: ₹177.9 crore (up from ₹136.6 crore in Q2 FY2026) – ~30.2% YoY growth . Key investor presentation takeaways from ICRA Ltd's Q2 FY27 inve
Motilal Oswal Financial Services Ltd (Q2 FY27)
Total Net Revenues for Q2FY27: ₹1,757 crore, up 20% YoY from ₹1,460 crore in Q2FY26 (Page 18). Key investor presentation takeaways from Motilal Oswal Financial
Indian Energy Ex (Q2 FY27)
Total Revenue (Standalone) Q2 FY’27: Rs 203.0 Cr, up from Rs 183.3 Cr in Q2 FY’26 (~10.7% YoY growth) . Key investor presentation takeaways from Indian Energy E

Compare:vs National Stock Exchange Of India Ltd vs BSE vs ICICI AMC

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

CARE Ratings Q2 FY22 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does CARE Ratings rank in Capital Markets?

Continue your research

What CARE Ratings's management said in earlier quarters

Others in Capital Markets this season